Koa Shoji Holdings
9273.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-06 | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|---|
| Revenue | ¥1.4bn | ¥1.3bn | ¥1.2bn | ¥1.1bn | ¥704m | ¥638m |
| Operating income | ¥749m | ¥718m | ¥643m | ¥511m | ¥86m | ¥74m |
| Ordinary income | ¥764m | ¥729m | ¥631m | ¥515m | ¥89m | ¥78m |
| Total assets | ¥14.7bn | ¥13.4bn | ¥13.2bn | ¥11.4bn | ¥11.9bn | ¥12.1bn |
| Net assets / equity | ¥12.3bn | ¥12.2bn | ¥12.1bn | ¥10.3bn | ¥10.3bn | ¥10.6bn |
| EPS (basic) | ¥17.46 | ¥16.63 | ¥15.55 | ¥12.44 | ¥2.41 | ¥1.93 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-07-01 → 2026-06-30 | Annual | 203 figures · EDINET |
18 more reports are still being processed.
Segments · FY ended 2026-06
| Segment | External sales | Profit |
|---|---|---|
| Drug Substance Sales Business | ¥15.7bn | ¥3.3bn |
| Pharmaceutical Marketing Business | ¥9.0bn | ¥2.1bn |
| Adjustments & eliminations | — | ¥40m |
| Total | ¥24.7bn | ¥5.4bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.